0001104659-23-070043.txt : 20230609 0001104659-23-070043.hdr.sgml : 20230609 20230609180158 ACCESSION NUMBER: 0001104659-23-070043 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230608 FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GILL DAVID N CENTRAL INDEX KEY: 0001106519 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38650 FILM NUMBER: 231006611 MAIL ADDRESS: STREET 1: C/O NXSTAGE MEDICAL INC. (NXTM) STREET 2: 439 SOUTH UNION STREET, 5TH FLOOR CITY: LAWRENCE STATE: MA ZIP: 01843 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc. CENTRAL INDEX KEY: 0001722964 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474619612 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 BUSINESS PHONE: 212-847-9841 MAIL ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 4 1 tm2318348-3_4seq1.xml OWNERSHIP DOCUMENT X0407 4 2023-06-08 0 0001722964 Y-mAbs Therapeutics, Inc. YMAB 0001106519 GILL DAVID N C/O Y-MABS THERAPEUTICS, INC. 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 1 0 0 0 0 Common Stock 2023-06-08 4 A 0 2330 0 A 2330 D Employee Stock Option (right to buy) 8.13 2023-06-08 4 A 0 13950 0 A 2033-06-08 Common stock 13950 13950 D Represents restricted stock units ("RSUs") granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockholders held in 2024, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on the vesting date. Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on each vesting date and are exercisable immediately upon vesting. /s/ Sune Reinholth Nyland, Attorney-in-Fact for David Gill 2023-06-09